Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edwin Ho

Cardiovascular Disease The Bronx, NY Medical Doctor

NPI 1467002246 CMS profile 6612718

111 East 210Th Street, Division Of Cardiology Administrative Offices, The Bronx, NY 10467

Open in the dashboard

General payments

$134,974

608 records reported · program years 2019–2025

Research payments

$7,563

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$224,879 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Edwin Ho of The Bronx, NY is reported in the CMS Open Payments database as having received $134,974 across 608 general payments and $7,563 in research payments paid to them. Separately, studies naming them as principal investigator received $224,879 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $74,527 202
2024 General $33,714 161
2024 Research $7,563 1
2023 General $8,790 91
2022 General $7,072 93
2021 General $8,055 45
2020 General $1,724 13
2019 General $1,092 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edwin Ho
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Edwin Ho were reported at $74,527. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Edwin Ho Cardiovascular Disease median Middle half National median
2019 $1,092 $450 $127–$1,392 $163
2020 $1,724 $242 $77–$751 $114
2021 $8,055 $335 $101–$1,037 $132
2022 $7,072 $395 $121–$1,211 $149
2023 $8,790 $443 $136–$1,283 $160
2024 $33,714 $450 $136–$1,323 $164
2025 $74,527 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $44,332 71 payments
  2. Medtronic, Inc. $35,849 192 payments
  3. Edwards Lifesciences Corporation $25,486 255 payments
  4. Ge Healthcare $13,300 10 payments
  5. Biosense Webster, Inc. $8,553 14 payments
  6. Boston Scientific Corporation $1,701 20 payments
  7. Medtronic Vascular, Inc. $1,318 10 payments
  8. CryoLife, Inc. $1,205 3 payments
  9. Philips Electronics North America Corporation $1,166 14 payments
  10. W. L. Gore & Associates, Inc. $820 6 payments
  11. Other $1,244 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $55,525 10 payments
  2. Food and Beverage $30,895 452 payments
  3. Travel and Lodging $30,599 140 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $14,000 3 payments
  5. Grant $2,404 1 payment
  6. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,551 2 payments
Products named General payments · program years 2019–2025
  1. NAVITOR $24,593 9 payments
  2. TRICLIP $15,726 16 payments
  3. Carto 3 $8,539 13 payments
  4. COREVALVE EVOLUT R $5,176 83 payments
  5. PASCAL $3,569 46 payments
  6. SAPIEN 3 Ultra RESILIA $2,463 47 payments
  7. Vivid $1,551 2 payments
  8. MITRACLIP $1,069 11 payments
  9. CoreValve Evolut $915 11 payments
  10. GORE CARDIOFORM Septal Occluder $820 6 payments
  11. Other $11,220 115 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $7,563 1 payment

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$57,610

Medicare's payments for the services billed

Medicare patients

417

Average age 77

Services billed

798

217 women, 200 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 73%
Arthritis 53%
Diabetes 51%
Chronic kidney disease 50%
Atrial fibrillation 47%
COPD 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

609 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record